Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Molecular Docking Analysis of SARS-CoV-2 Inhibitor N3 (6LU7) against Selected Flavonoids and Vitamins

Author(s): Sunil Junapudi*, Yasodha Krishna Janapati, Susmitha Uppugalla, Timothy Harris, Muhammad Yaseen and Muhammad Latif*

Volume 4, Issue 4, 2023

Published on: 24 October, 2023

Article ID: e181023222301 Pages: 8

DOI: 10.2174/0126667975261384231010181117

Price: $65

Abstract

Background: Coronavirus is a zoonotic disease and transmits between animals and humans. The disease known as COVID-19 (SARS-CoV-2) has become a pandemic since its outbreak. In addition to vaccines, a combination of antiretroviral agents, chloroquine derivatives, and vitamins are being used to treat SARS-CoV-2.

Method: We performed molecular docking analysis of SARS-CoV-2 inhibitor N3 (6LU7) using a series of flavonoid derivatives and vitamins. The X-ray crystallographic 3D structures of COVID-19 main protease in complex with an inhibitor N3 (PDB code: 6LU7, resolution 2.16 Å complexed with a selective substance) were downloaded from the online Protein Data Bank. The structures of the ligands and protein were constructed using ChemDrawUltra 8.0. The docking process, interactions, and binding of ligands were visualized using the software Molegro Virtual Dockings (MVD). The physicochemical and toxicity characteristics of tested flavonoid derivatives and vitamins were determined using Swiss-ADME and pkCSM online software. We found that molecular docking scores were between -64.42 and –172.00 Kcal/mol. The H-bonding and steric interactions were compared with other flavonoid derivatives. The ADMET parameters suggested that compounds 4, 68, 90, 92, and 94 have a higher GI rate.

Results: Our results also indicated that compound 78 was more potent and had higher skin permeation than other flavonoid derivatives. The study showed that the compounds 5, 28, 74, 78, and folic acid fitted well in the active site of COVID-19 inhibitor N3 (6LU7) and interacted with the residues in the active site, which are essential for their biological activity.

Conclusion: Therefore, compounds 5, 28, 74, and 78 and folic acid can be a COVID-19 inhibitor N3 (6LU7) and might be used in the treatment of COVID-19 infection.

Graphical Abstract

[1]
Raman R, Patel KJ, Ranjan K. COVID-19: Unmasking emerging SARS-CoV-2 variants, vaccines and therapeutic strategies. Biomolecules 2021; 11(7): 993.
[http://dx.doi.org/10.3390/biom11070993] [PMID: 34356617]
[2]
Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin Microbiol Infect 2022; 28(2): 202-21.
[http://dx.doi.org/10.1016/j.cmi.2021.10.005] [PMID: 34715347]
[3]
Ciotti M, Ciccozzi M, Pieri M, Bernardini S. The COVID-19 pandemic: Viral variants and vaccine efficacy. Crit Rev Clin Lab Sci 2022; 59(1): 66-75.
[http://dx.doi.org/10.1080/10408363.2021.1979462] [PMID: 34598660]
[4]
Saha T, Khadka P, Das SC. Alcohol-based hand sanitizer-composition, proper use and precautions. Germs 2021; 11(3): 408-17.
[http://dx.doi.org/10.18683/germs.2021.1278] [PMID: 34722363]
[5]
Nigussie H. The coronavirus intervention in Ethiopia and the challenges for implementation. Front Commun 2021; 6: 562512.
[http://dx.doi.org/10.3389/fcomm.2021.562512]
[6]
Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol 2020; 92(4): 441-7.
[http://dx.doi.org/10.1002/jmv.25689] [PMID: 31994742]
[7]
Setti L, Passarini F, De Gennaro G, et al. Airborne transmission route of COVID-19: Why 2 meters/6 feet of inter-personal distance could not be enough. Int J Environ Res Public Health 2020; 17(8): 2932.
[http://dx.doi.org/10.3390/ijerph17082932] [PMID: 32340347]
[8]
Cheng VCC, Wong SC, Chuang VWM, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. J Infect 2020; 81(1): 107-14.
[http://dx.doi.org/10.1016/j.jinf.2020.04.024] [PMID: 32335167]
[9]
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382(13): 1199-207.
[http://dx.doi.org/10.1056/NEJMoa2001316] [PMID: 31995857]
[10]
Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18): 1708-20.
[http://dx.doi.org/10.1056/NEJMoa2002032] [PMID: 32109013]
[11]
Ayittey FK, Ayittey MK, Chiwero NB, Kamasah JS, Dzuvor C. Economic impacts of Wuhan 2019‐nCoV on China and the world. J Med Virol 2020; 92(5): 473-5.
[http://dx.doi.org/10.1002/jmv.25706] [PMID: 32048740]
[12]
Reported Cases and Deaths by Country or Territory. Available from: https://www.worldometers.info/coronavirus/#countries (Accessed on: June 25. 2022).
[13]
Khunti K, Singh AK, Pareek M, Hanif W. Is ethnicity linked to incidence or outcomes of covid-19? BMJ 2020; 369: m1548.
[http://dx.doi.org/10.1136/bmj.m1548] [PMID: 32312785]
[14]
Basha SH. Corona virus drugs-a brief overview of past, present and future. Journal of PeerScientist 2020; 2(2): e1000013.
[15]
WHO CO Responding to Community Spread of COVID-19 Reference 2020. Available from:WHO/COVID-19/Community_Transmission/20201
[16]
Calder PC. Nutrition and immunity: Lessons for COVID-19. Nutr Diabetes 2021; 11(1): 19.
[http://dx.doi.org/10.1038/s41387-021-00165-0] [PMID: 34168111]
[17]
Heymann DL, Shindo N. COVID-19: What is next for public health? Lancet 2020; 395(10224): 542-5.
[http://dx.doi.org/10.1016/S0140-6736(20)30374-3] [PMID: 32061313]
[18]
Inglesby TV. Public health measures and the reproduction number of SARS-CoV-2. JAMA 2020; 323(21): 2186-7.
[http://dx.doi.org/10.1001/jama.2020.7878] [PMID: 32356869]
[19]
Calder PC, Kew S. The immune system: A target for functional foods? Br J Nutr 2002; 88(S2) (Suppl. 2): S165-76.
[http://dx.doi.org/10.1079/BJN2002682] [PMID: 12495459]
[20]
Dabeek WM, Marra MV. Dietary Quercetin and Kaempferol: Bioavailability and potential cardiovascular-related bioactivity in humans. Nutrients 2019; 11(10): 2288.
[http://dx.doi.org/10.3390/nu11102288] [PMID: 31557798]
[21]
Salehi B, Fokou P, Sharifi-Rad M, et al. The therapeutic potential of Naringenin: A review of clinical trials. Pharmaceuticals 2019; 12(1): 11.
[http://dx.doi.org/10.3390/ph12010011] [PMID: 30634637]
[22]
Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004; 318(3): 719-25.
[http://dx.doi.org/10.1016/j.bbrc.2004.04.083] [PMID: 15144898]
[23]
Yang R, Liu H, Bai C, et al. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study. Pharmacol Res 2020; 157: 104820.
[http://dx.doi.org/10.1016/j.phrs.2020.104820] [PMID: 32360484]
[24]
Zhong LLD, Lam WC, Yang W, et al. Potential targets for treatment of Coronavirus Disease 2019 (COVID-19): A review of Qing-Fei-Pai-Du-Tang and its major herbs. Am J Chin Med 2020; 48(5): 1051-71.
[http://dx.doi.org/10.1142/S0192415X20500512] [PMID: 32668969]
[25]
Wu H, Wang J, Yang Y, et al. Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology. Yao Xue Xue Bao 2020; 55(03): 374-83.
[26]
Liu X, Zhang B, Jin Z, Yang H, Rao Z. The crystal structure of COVID-19 main protease in complex with an inhibitor N3 (PDB DOI
[27]
Singh M, Kaur M, Silakari O. Flavones: An important scaffold for medicinal chemistry. Eur J Med Chem 2014; 84: 206-39.
[http://dx.doi.org/10.1016/j.ejmech.2014.07.013] [PMID: 25019478]
[28]
Jin Z, Du X, Xu Y, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020; 582(7811): 289-93.
[http://dx.doi.org/10.1038/s41586-020-2223-y] [PMID: 32272481]
[29]
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[30]
Available from: http://www.swissadme.ch/
[31]
Pharmacokinetic properties. Available from: http://biosig.unimelb.edu.au/pkcsm/prediction
[32]
Daina A, Michielin O, Zoete V. iLOGP: A simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach. J Chem Inf Model 2014; 54(12): 3284-301.
[http://dx.doi.org/10.1021/ci500467k] [PMID: 25382374]
[33]
Lagorce D, Reynes C, Camproux A-C, Miteva MA, Sperandio O, Villoutreix BO. In silico ADME/Tox predictions. ADMET for Medicinal Chemists 2011; pp. 29-124.
[34]
Obermeier B, Verma A, Ransohoff RM. The blood–brain barrier. Handb Clin Neurol 2016; 133: 39-59.
[http://dx.doi.org/10.1016/B978-0-444-63432-0.00003-7] [PMID: 27112670]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy